You are here

HEXO Corp reports $6.7 million in gross revenue for the first quarter of new fiscal year

  • Sales of $5.2 million for adult-use cannabis during the first two weeks of legalization in Canada
  • Creation of Truss, a partnership with Molson Coors Canada in support of the Company’s objective to partner with Fortune 500 companies in various product categories and leverage their distribution and brand platforms
  • Acquisition of a scalable facility in Belleville, Ontario to establish a centre of excellence for cannabis-based consumer packaged products
  • 1 million sq. ft. facility on track to be operational by end of December 2018
  • First foothold in Europe: partnership in Greece to establish a Eurozone distribution centre

GATINEAU, Quebec, Dec. 13, 2018 (GLOBE NEWSWIRE) -- HEXO Corp. (TSX:HEXO) (the "Company") is reporting its financial results for the first quarter of the 2019 fiscal year. Gross revenue for the quarter reached $6.7 million, which includes $5.2 million in sales of adult-use cannabis in the first two weeks following legalization in Canada.

“HEXO hit tremendous milestones in the weeks following the legalization of adult-use cannabis,” said HEXO’s CEO and co-founder Sebastien St-Louis. “The Company continues to honour its commitment to executing on its plans, which has led to a significant portion of our first quarter’s $6.7 million in revenue generated in just two weeks and represents more than a 500% increase over last quarter.”

“HEXO’s first quarter financials highlight the remarkable pace of its adult-use cannabis sales and puts HEXO on-track to generate significant revenue this year”, added Mr. St-Louis. “Today, we are a world-class organization as our team continues to focus on our strategy which includes partnering with Fortune 500 companies in various product categories and leverage their distribution platforms.”

Other financial highlights include:

  • Approximately 1,110,000 total gram equivalents sold in the quarter versus 539,000 in total fiscal 2018
  • Gross revenue per gram of $5.45 in the adult-use market and $9.12 in the medical market
  • 2% increase over last quarter in medical cannabis sales despite the new adult-use market
  • Filing of a shelf prospectus to make offering of up to $800 million valid for a 25-month period
  • Conclusion of the three-month Canada-wide Never Jaded tour featuring Wu Tang Clan, Our Lady Peace, Tristan Eaton and Matty Matheson

During the quarter ended October 31, 2018, the Company produced over 3,550 kg of dried cannabis. Certain production areas of the existing licensed facilities have been dedicated to the commissioning of the new 1,000,000 sq. ft. facility. This includes designated areas housing the mother plants to be relocated to the 1,000,000 sq. ft. facility, as well as a cutting area to supply the 1,000,000 sq. ft. facility with its first plants. The Company is ramping up towards its full production capacity, with efficiency gains and increased capacity achieved through the recently licensed 250,000 sq. ft. facility and the additional 1,000,000 sq. ft. facility, which will become operational at the end of the calendar year. The Company expects to achieve its run goal rate of 108,000 kg of annual dried flower production.

Additionally, the Company recently launched its new corporate website www.hexocorp.com. The corporate website houses information about HEXO’s career opportunities, management, corporate social responsibility program, investor relations and press releases, and links to HEXO’s brand websites.

The management discussion and analysis for the period and the accompanying financial statements and notes are available under the Company's profile on SEDAR at www.sedar.com and on its website at www.HEXO.com. All amounts are expressed in Canadian dollars.

First Quarter 2019 Financial Results

Summary of results for the three-month period ended October 31, 2018 and October 31, 2017 (in thousands of Canadian dollars, except share and per share amounts, and where otherwise noted)

Summary of results for the three-month period ended October 31, 2018 and October 31, 2017:

  For the three months ended
Income statement snapshotOctober 31, 2018 October 31, 2017
 Gross revenue$  6,677 $  1,102 
 Excise taxes$  (1,014 )$  –  
 Net revenue$  5,663 $  1,102 
 Gross margin before fair value adjustments $  2,832 $  639 
 Gross margin$  7,237 $  2,463 
 Operating expenses$  22,035 $  2,844 
 (Loss)/income from operations$  (14,797 )$  (381)
 Other income/(expenses) $  1,994 $  (1,537)
 Net income (loss)$  (12,803 )$  (1,918)
 Weighted average shares outstanding 194,033,380  76,480,085 
 Net income (loss) per share$  (0.07 )$  (0.03)


  Q1 ’19Q4 ’18Q3 ’18Q2 ’18Q1 ’18
Revenue    
  
 Adult-use cannabis revenue1$  5,194$  -$  -$  -$  -
 Dried grams and gram equivalents sold   952,223   -   -   -   -
 Adult-use revenue/gram equivalent$  5.45$  -$  -$  -$  -
 Medical cannabis revenue1 $    1,436 $  1,410$     1,240$    1,182$    1,102
 Dried grams and gram equivalents sold     157,504    152,288    134,253    131,501    120,844
 Medical revenue/gram equivalent $    9.12 $    9.26$     9.24$  8.99$    9.12
 Ancillary revenue2$    47$  -$  -$  -$    -
 Total sales$     6,677$  1,410$  1,240$  1,182$    1,102
       

1 Cannabis revenue represents adult-use and medical market sales under the normal course of business and is exclusive of excise taxes.
2 Revenue outside of the primary operations of the Company.

Total revenue in the first quarter of fiscal 2019 increased to $6,677 from $1,102 in the compared period of fiscal 2018. The main contributor is the introduction of adult-use sales in the final two weeks of the quarter which accounted for 78% of total revenue. New in the period is $47 of ancillary non-direct cannabis sales revenue related to a management agreement.

ADULT-USE SALES

The Company realized its first adult-use revenues during the first quarter of fiscal 2019. Adult-use sales totaled $5,194 in this period which is a 371% increase over the $1,102 of medical sales in the first quarter of 2018, and a 5% increase over the $4,934 of total medical sales in all of fiscal 2018. This is a direct result of the Company’s introductory brand awareness campaign.

Sales volume in the first quarter of 2019 was 952,223 gram equivalents sold. Dried flower represented 81% of gram equivalents sold during the period.    

Adult-use revenue per gram equivalent was $5.45. This is reflective of 81% of these sales pertaining to dried flower which command a competitive market sales price. The remaining balance primarily represents oil sales which command a higher revenue per gram equivalent. 

During the period, 90% of all adult-use sales were realized in Quebec through the SQDC with the remaining 10% derived in Ontario and British Columbia via the OCS and BCLDB respectively.

MEDICAL SALES

Revenue for the first quarter ended October 31, 2018 increased 30% to $1,436 compared to $1,102 in the same period in fiscal 2018. Higher revenue was driven by increased sales volume as well higher Elixir oil sales which command a higher revenue per gram when compared to dried gram sales. Compared to the prior quarter, the sequential revenue increase was 2% reflecting a lower revenue per gram on the dried flower sales which decreased $0.22/gram due to the current period’s sales mix of products.

Sales volume increased 30% to 157,504 gram equivalents, compared to 120,844 in the same prior year period, due to an increase in our oil-based products as the product mix purchased by customers shifted towards smoke-free alternatives. Total dried grams sold increased 10% when compared to the same prior year period. Revenue per gram equivalent remained at $9.12 as compared the same prior year period. On a sequential basis, sales volume collectively increased 3% across both dried and oil sales.

Geographical sales in Ontario and Quebec increased 8% and 16% respectively.

Cost of Sales and Excise Taxes

Cost of goods sold includes the direct and indirect costs of materials and labour related to inventory sold, and includes harvesting, processing, packaging, shipping costs, depreciation and applicable overhead.

Fair value adjustment on sale of inventory includes the fair value of biological assets included in the value of inventory transferred to cost of sales.

Fair value of biological assets represents the increase or decrease in fair value of plants during the growing process less expected cost to complete and selling costs and includes certain management estimates.

  For the three months ended 
   

October 31, 2018
October 31, 2017 
 Excise taxes$  1,014 $  –  
    
 Cost of sales   2,831    463 
    
 Fair value adjustment on sale of inventory   717    814 
 Fair value adjustment on biological assets   (5,123 )   (2,639)
 Total fair value adjustment$  (4,406 )$  (1,825)

Cost of sales for the quarter ended October 31, 2018 were $2,831, compared to $463 for the same quarter ended in fiscal 2018. The increase in cost of sales is the result of increased sales volumes and increases to transformation costs as the oil and other value added product production mix has increased from the first quarter of fiscal 2018. 

Fair value adjustment on the sale of inventory for the first quarter ended October 31, 2018 was $717 compared to $814 for the same quarter ended October 31, 2018. This variance is due to increased sales volume of inventory sold when compared to the same quarter in fiscal year 2018 and the reversal of the previously recognized net realizable impairment on dried inventory. 

Fair value adjustment on biological assets for the quarter ended October 31, 2018 was ($5,123) compared to ($2,639) for the same quarter ended in fiscal 2018. This variance is due to the increase in the total number of plants as the first harvests and first full quarter of the B6 greenhouse being active. This results in significantly increased expected gram yields in the quarter and increased production costs of operating a newly in-use facility. The increase in scale and total plants on hand is the result of preparing for the adult-use market, which began October 17, 2018. 

New in the period were excise taxes associated with the first adult-use and medical recognized revenues post legalization between October 17, 2018 and October 31, 2018. These taxes totaled $1,014 and reduced the total gross margin by approximately 13%. Excise taxes are a function of fixed provincial and territorial rates based upon the gram equivalents sold as well as a variable ad valorem component which is dependent upon the selling price of the products.   

Operating Expenses

   For the three months ended
  October 31, 2018
October 31, 2017
General and administration $  4,912 $  1,168
Marketing and promotion    11,711    1,115
Stock-based compensation    4,689    314
Amortization of property, plant and equipment    573    124
Amortization of intangible assets    150    63
Research and development  -   61
Total $  22,035 $  2,844

Operating expenses include marketing and promotion, general and administrative, research and development, stock-based compensation, and amortization expenses. Marketing and promotion expenses include customer acquisition costs, customer experience costs, salaries for marketing and promotion staff, general corporate communications expenses, and research and development costs. General and administrative expenses include salaries for administrative staff and executive salaries as well as general corporate expenditures including legal, insurance and professional fees.

GENERAL AND ADMINISTRATIVE

General and administrative expenses increased to $4,912 in the first quarter, compared to $1,168 for the same period in fiscal 2018. This increase reflects the general growing scale of our operations, including an increase in general, finance and administrative staffing and additional rental space. Total general and administrative payroll increased $2,063 due to the growth in operations. Total professional fees increased by $710, as a result of the increased financial reporting and control-based regulatory requirements accompanying public status on the TSX, additional legal fees pertaining to agreements such as the joint ventures established in the period, recruiting fees and increased compliance costs as a publicly listed company.

MARKETING AND PROMOTION

Marketing and promotion expenses significantly increased to $11,711 in the first quarter, compared to $1,115 for the same period in fiscal 2018. This reflects the launch of adult-use marketing and promotional events undertaken in the quarter as we build brand recognition and establish HEXO in the cannabis market. This is inclusive of higher staff and travel-related expenses, printing and promotional materials as well as advertisement costs.

AMORTIZATION OF PROPERTY, PLANT AND EQUIPMENT

Amortization of property, plant and equipment increased to $573 in the quarter, compared with $124 for the same period in fiscal 2018. The increase is the direct result of the Company’s newly built greenhouses and acquired cultivation equipment. Additionally, increases to cultivation and production equipment were incurred in order to support the larger production demands and scalability of the Company.

AMORTIZATION OF INTANGIBLE ASSETS

Amortization of intangible assets increased to $150 in the first quarter, compared with $63 for the same period in fiscal 2018. The increase is the result of the implementation of the first phase of a new ERP system, which will replace certain software programs we currently use and capitalized licenses and web based assets.

Loss from Operations

Income/(loss) from operations for the first quarter was ($14,797), compared to ($381) for the same period in fiscal 2018. The increased loss from operations is due mainly to higher expenses in line with the expanding scale of operations as we prepared for the legalization of the adult-use market and the realization of stock-based compensation expenses in line with the increased headcount and market share price value of the Company.

Other Income/Expenses

Other income/(expense) was $1,994 for the three months ended October 31, 2018 compared to ($1,537) in the same period of fiscal 2018. Revaluation of financial instruments of ($2,337) in the latest quarter reflects the revaluation of an embedded derivative related to USD denominated warrants issued in the prior year. Additionally, we had an unrealized fair value gain on convertible debenture receivable of $3,434. Interest income of $1,066 was realized for the three months ended October 31, 2018 reflective of the interest generated from the increased short-term investments held as at October 31, 2018.

About HEXO Corp.

HEXO Corp. creates and distributes innovative, easy-to-use and easy-to-understand products to serve the Canadian cannabis market. One of the country’s lowest-cost producers, HEXO is rapidly increasing its production capacity in the lead up to the adult-use cannabis market. The Company currently operates with over 310,000 sq. ft. of production capacity with construction on another 1,000,000 sq. ft. expansion set to be complete by year end. HEXO will serve the adult-use market under the HEXO brand, while continuing to serve its medical cannabis clients through the well-known Hydropothecary brand.  

Forward-Looking Information

This press release may contain forward-looking information that is based on certain assumptions and involves known and unknown risks and uncertainties and other factors that could cause actual events to differ materially from current assumptions and expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. A more complete discussion of the risks and uncertainties facing the Company appears in the Company’s Annual Information Form and continuous disclosure filings, which are available on SEDAR’s website at www.sedar.com. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements as a result of new information or future events, or for any other reason.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Investor Relations:
Kathy Chow
1-866-438-8429
invest@HEXO.com 
www.ir.hexo.com

Media Relations:
Sarah Brown
media@hexo.com

Director
Adam Miron
819-639-5498

Thursday, December 13, 2018 - 07:11